For Immediate Release
September 20, 2023
Cranford, NJ – WBB Securities and WBB Research Institute sponsored a Demy/Colton Salon on September 20, 2023, “Exploring Solid Tumor Treatment At Its Core: a Conversation with Prominent KOLS and Its Future” A presentation and discussion that featured up-to-date information about the role of iRGD peptides in penetrating the protective stroma that surrounds cancer cells and reducing cancer’s ability to resist the immune system, thus enhancing the effectiveness of anti-cancer therapies and inhibiting metastasis.
This Virtual Salon was co-moderated by Anette Breindl, Ph.D., Managing Director of BioWorld Science, and Steve Brozak, DMH, Managing Partner and President of WBB Securities. The Salon also featured the winner of the Albert Lasker Basic Medical Research Award, Lasker, Erkki Ruoslahti, MD, Ph.D.; Assistant Professor of Surgery at Columbia University, Kazuki N. Sugahara, MD, Ph.D.; The head of the Department of Medical Oncology at SJOG Subiaco, Andrew Dean, MBChB, MRCP (UK), FRACP, and David J. Mazzo, Ph.D., CEO of Lisata Therapeutics, which is developing the iRDG peptide (LSTA).
About WBB Securities.
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily on the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer, a member of FINRA, and a state-registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
About WBB Research Institute.
The WBB Research Institute is a newly formed, independent, non-ideological, public policy research center fostering and applying specialized knowledge to various health issues.
About Demy-Colton.
Demy Colton is a leader in biotech and life science events; with over 20 years of experience connecting leaders of innovative biotech companies with key stakeholders, investors, and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
